Literature DB >> 15599217

Imatinib (Gleevec)-induced hepatotoxicity.

Walid S Ayoub1, Stephen A Geller, Tram Tran, Paul Martin, John M Vierling, F Fred Poordad.   

Abstract

Imatinib (Gleevec, Novartis Pharmaceuticals Corp, East Hanover, NJ) is widely used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. To our knowledge, only one case report of histologically proven Imatinib-induced hepatotoxicity has been reported. We describe another case of hepatotoxicity in a 22-year-old woman including the histopathologic changes and the clinical course after the discontinuation of Imatinib.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15599217

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN： 0192-0790            Impact factor:   3.062


  15 in total

1.  Imatinib mesylate (gleevec) hepatotoxicity.

Authors:  Ayse L Mindikoglu; Arie Regev; Pablo A Bejarano; Enrique J Martinez; Lennox J Jeffers; Eugene R Schiff
Journal:  Dig Dis Sci       Date:  2007-01-12       Impact factor: 3.199

2.  Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes.

Authors:  Noelia Nebot; Severine Crettol; Fabrizio d'Esposito; Bruce Tattam; David E Hibbs; Michael Murray
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

3.  Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors.

Authors:  Onder Tonyali; Ugur Coskun; Ramazan Yildiz; Tarkan Karakan; Umut Demirci; Nalan Akyurek; Mustafa Benekli; Suleyman Buyukberber
Journal:  Med Oncol       Date:  2009-08-07       Impact factor: 3.064

4.  A central role for CD68(+) macrophages in hepatopulmonary syndrome. Reversal by macrophage depletion.

Authors:  Thenappan Thenappan; Ankush Goel; Glenn Marsboom; Yong-Hu Fang; Peter T Toth; Hannah J Zhang; Hidemi Kajimoto; Zhigang Hong; Jonathan Paul; Christian Wietholt; Jennifer Pogoriler; Lin Piao; Jalees Rehman; Stephen L Archer
Journal:  Am J Respir Crit Care Med       Date:  2010-12-10       Impact factor: 21.405

Review 5.  Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity.

Authors:  Ayako Arai; Weihua Yan; Shihoko Wakabayashi; Shin Hayashi; Johji Inazawa; Osamu Miura
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

6.  Imatinib-induced fatal acute liver failure.

Authors:  Ezequiel Ridruejo; Roberto Cacchione; Alejandra G Villamil; Sebastián Marciano; Adrián C Gadano; Oscar G Mandó
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

Review 7.  Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia.

Authors:  Shelby D Reed; Kevin J Anstrom; Yanhong Li; Kevin A Schulman
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

8.  Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients.

Authors:  Cen Xie; Jialan Zhou; Zitao Guo; Xingxing Diao; Zhiwei Gao; Dafang Zhong; Haoyuan Jiang; Lijia Zhang; Xiaoyan Chen
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

Review 9.  Gastrointestinal and hepatic complications of hematopoietic stem cell transplantation.

Authors:  Hande H Tuncer; Naveed Rana; Cannon Milani; Angela Darko; Samer A Al-Homsi
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

10.  Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report.

Authors:  Baidehi Maiti; Sebouh Setrakian; Hamed A Daw
Journal:  Cases J       Date:  2009-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.